Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Skin Cancer Specialty Channel

FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
News
‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma
02/21/2024
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that...
02/21/2024
Oncology
News
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
02/20/2024
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an...
02/20/2024
Oncology
News
Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma
02/15/2024
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective...
02/15/2024
Oncology
News
Neoadjuvant Toripalimab Plus Axitinib Demonstrates Promising Response Among Patients With Resectable Mucosal Melanoma
12/14/2023
According to results from a phase 2 trial, neoadjuvant toripalimab plus axitinib resulted in promising pathologic response rates among patients with resectable, metastatic mucosal melanoma.
According to results from a phase 2 trial, neoadjuvant toripalimab plus axitinib resulted in promising pathologic response rates among patients with resectable, metastatic mucosal melanoma.
According to results from a...
12/14/2023
Oncology
Conference Coverage
Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma
11/22/2023
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients...
11/22/2023
Oncology
Conference Coverage
Neoadjuvant/Adjuvant Pembrolizumab For Patients With Resectable, Stage IIIB-IV Melanoma
11/02/2023
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
According to pathologic response...
11/02/2023
Oncology
Conference Coverage
Avelumab Plus Cetuximab Exhibits High Clinical Activity, Tolerable Safety in Advanced Cutaneous Squamous Cell Carcinoma
10/17/2023
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Avelumab plus cetuximab...
10/17/2023
Oncology
News
FDA Approves Adjuvant Nivolumab for Resected, Stage IIB/C Melanoma
10/16/2023
Based on findings from the phase 3 CHECKMATE-76K trial, the FDA has approved nivolumab in the adjuvant setting for patients 12 and older with completely resected stage IIB/C melanoma.
Based on findings from the phase 3 CHECKMATE-76K trial, the FDA has approved nivolumab in the adjuvant setting for patients 12 and older with completely resected stage IIB/C melanoma.
Based on findings from the phase...
10/16/2023
Oncology
News
Addition of Binimetinib to Encorafenib Demonstrated Efficacy, Safety Among Patients With Advanced, Unresectable BRAFV600-Mutant Melanoma
09/11/2023
According to results from part 2 of the phase 3 COLUMBUS trial, the addition of binimetinib to encorafenib improved progression-free survival, overall response rate, and had a favorable safety profile compared with encorafenib alone among...
According to results from part 2 of the phase 3 COLUMBUS trial, the addition of binimetinib to encorafenib improved progression-free survival, overall response rate, and had a favorable safety profile compared with encorafenib alone among...
According to results from part 2...
09/11/2023
Oncology
News
Perioperative Pembrolizumab Demonstrates Long-Term Safety, Efficacy Among Patients With Late-Stage, Resectable Cutaneous Melanoma
09/01/2023
According to 5-year follow-up results from a phase 1b study, pembrolizumab is safe and effective in both the neoadjuvant and adjuvant settings among patients with resectable, stage III to IV cutaneous melanoma who have achieved a pathological...
According to 5-year follow-up results from a phase 1b study, pembrolizumab is safe and effective in both the neoadjuvant and adjuvant settings among patients with resectable, stage III to IV cutaneous melanoma who have achieved a pathological...
According to 5-year follow-up...
09/01/2023
Oncology

Advertisement

News

News
‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma
02/21/2024
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that...
02/21/2024
Oncology
News
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
02/20/2024
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an...
02/20/2024
Oncology
News
Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma
02/15/2024
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective...
02/15/2024
Oncology
News
Neoadjuvant Toripalimab Plus Axitinib Demonstrates Promising Response Among Patients With Resectable Mucosal Melanoma
12/14/2023
According to results from a phase 2 trial, neoadjuvant toripalimab plus axitinib resulted in promising pathologic response rates among patients with resectable, metastatic mucosal melanoma.
According to results from a phase 2 trial, neoadjuvant toripalimab plus axitinib resulted in promising pathologic response rates among patients with resectable, metastatic mucosal melanoma.
According to results from a...
12/14/2023
Oncology
Conference Coverage
Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma
11/22/2023
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients...
11/22/2023
Oncology
Conference Coverage
Neoadjuvant/Adjuvant Pembrolizumab For Patients With Resectable, Stage IIIB-IV Melanoma
11/02/2023
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
According to pathologic response...
11/02/2023
Oncology
Conference Coverage
Avelumab Plus Cetuximab Exhibits High Clinical Activity, Tolerable Safety in Advanced Cutaneous Squamous Cell Carcinoma
10/17/2023
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Avelumab plus cetuximab...
10/17/2023
Oncology
News
FDA Approves Adjuvant Nivolumab for Resected, Stage IIB/C Melanoma
10/16/2023
Based on findings from the phase 3 CHECKMATE-76K trial, the FDA has approved nivolumab in the adjuvant setting for patients 12 and older with completely resected stage IIB/C melanoma.
Based on findings from the phase 3 CHECKMATE-76K trial, the FDA has approved nivolumab in the adjuvant setting for patients 12 and older with completely resected stage IIB/C melanoma.
Based on findings from the phase...
10/16/2023
Oncology
News
Addition of Binimetinib to Encorafenib Demonstrated Efficacy, Safety Among Patients With Advanced, Unresectable BRAFV600-Mutant Melanoma
09/11/2023
According to results from part 2 of the phase 3 COLUMBUS trial, the addition of binimetinib to encorafenib improved progression-free survival, overall response rate, and had a favorable safety profile compared with encorafenib alone among...
According to results from part 2 of the phase 3 COLUMBUS trial, the addition of binimetinib to encorafenib improved progression-free survival, overall response rate, and had a favorable safety profile compared with encorafenib alone among...
According to results from part 2...
09/11/2023
Oncology
News
Perioperative Pembrolizumab Demonstrates Long-Term Safety, Efficacy Among Patients With Late-Stage, Resectable Cutaneous Melanoma
09/01/2023
According to 5-year follow-up results from a phase 1b study, pembrolizumab is safe and effective in both the neoadjuvant and adjuvant settings among patients with resectable, stage III to IV cutaneous melanoma who have achieved a pathological...
According to 5-year follow-up results from a phase 1b study, pembrolizumab is safe and effective in both the neoadjuvant and adjuvant settings among patients with resectable, stage III to IV cutaneous melanoma who have achieved a pathological...
According to 5-year follow-up...
09/01/2023
Oncology

Interactive Features

Test Your Knowledge
Quiz: Nomograms Developed to Predict Recurrences in Patients with T1 Melanomas
03/26/2021
True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.
True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.
True or False: The nomograms in...
03/26/2021
Oncology
Test Your Knowledge
Quiz: Does Cosibelimab Yield Benefit mCSCC?
09/22/2020
True or False: Cosibelimab has a predictable and manageable safety profile and demonstrated robust clinical activity in mCSCC patient, including durable complete and partial responses.
True or False: Cosibelimab has a predictable and manageable safety profile and demonstrated robust clinical activity in mCSCC patient, including durable complete and partial responses.
True or False: Cosibelimab has a...
09/22/2020
Oncology
Test Your Knowledge
Quiz: Promising Advances in the Melanoma Space May Lead to Improved Patient Outcomes
09/02/2020
Treatments for melanoma brain metastasis changed between 2007 and 2016 with the advent of new radiotherapy techniques, targeted therapeutic agents, and ______ ?
Treatments for melanoma brain metastasis changed between 2007 and 2016 with the advent of new radiotherapy techniques, targeted therapeutic agents, and ______ ?
Treatments for melanoma brain...
09/02/2020
Oncology
Test Your Knowledge
Quiz: Pembrolizumab for the Treatment of cSCC
07/20/2020
True or False: Has pembrolizumab been approved by the FDA for use in patients with cSCC?
True or False: Has pembrolizumab been approved by the FDA for use in patients with cSCC?
True or False: Has pembrolizumab...
07/20/2020
Oncology
Test Your Knowledge
Quiz: Combining Low-Dose Ipilimumab With Pembrolizumab in Melanoma
06/22/2020
True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.
True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.
True or False: In a phase 2...
06/22/2020
Oncology
Test Your Knowledge
Quiz: What Factors Increase Risk for AEs in Patients With Melanoma?
05/25/2020
True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.
True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.
True or False: The risk for...
05/25/2020
Oncology
Test Your Knowledge
Quiz: Can Adverse Events Indicate Pembrolizumab Activity in Stage III Melanoma?
03/06/2020
True or False: Immune-related adverse events can be indicative of pembrolizumab activity in patients with high-risk, stage III melanoma.
True or False: Immune-related adverse events can be indicative of pembrolizumab activity in patients with high-risk, stage III melanoma.
True or False: Immune-related...
03/06/2020
Oncology
Test Your Knowledge
Quiz: Mohs Micrographic Surgery vs Traditional Excision for Melanoma
02/13/2020
True or False: Compared with excision, Mohs micrographic surgery moderately improves overall survival in patients with early-stage invasive melanoma.
True or False: Compared with excision, Mohs micrographic surgery moderately improves overall survival in patients with early-stage invasive melanoma.
True or False: Compared with...
02/13/2020
Oncology
Test Your Knowledge
Quiz: Association of Progression of Metastatic Disease and Time to First Distant Recurrence in Melanoma
05/28/2019
True or false: A recent study found no association between progression of metastatic disease and time to first distant recurrence in patients with melanoma.
True or false: A recent study found no association between progression of metastatic disease and time to first distant recurrence in patients with melanoma.
True or false: A recent study...
05/28/2019
Oncology
Test Your Knowledge
Quiz: Promising First-Line Therapy for Merkel Cell Carcinoma
03/27/2019
Which of the following yielded durable responses, a manageable safety profile, and survival favorable to that of first-line chemotherapy in a recent study of patients with advanced Merkel cell carcinoma?
Which of the following yielded durable responses, a manageable safety profile, and survival favorable to that of first-line chemotherapy in a recent study of patients with advanced Merkel cell carcinoma?
Which of the following yielded...
03/27/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma
02/21/2024
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that...
02/21/2024
Oncology
News
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
02/20/2024
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an...
02/20/2024
Oncology
News
Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma
02/15/2024
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective...
02/15/2024
Oncology
News
Neoadjuvant Toripalimab Plus Axitinib Demonstrates Promising Response Among Patients With Resectable Mucosal Melanoma
12/14/2023
According to results from a phase 2 trial, neoadjuvant toripalimab plus axitinib resulted in promising pathologic response rates among patients with resectable, metastatic mucosal melanoma.
According to results from a phase 2 trial, neoadjuvant toripalimab plus axitinib resulted in promising pathologic response rates among patients with resectable, metastatic mucosal melanoma.
According to results from a...
12/14/2023
Oncology
Conference Coverage
Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma
11/22/2023
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients...
11/22/2023
Oncology
Conference Coverage
Neoadjuvant/Adjuvant Pembrolizumab For Patients With Resectable, Stage IIIB-IV Melanoma
11/02/2023
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
According to pathologic response...
11/02/2023
Oncology
Conference Coverage
Avelumab Plus Cetuximab Exhibits High Clinical Activity, Tolerable Safety in Advanced Cutaneous Squamous Cell Carcinoma
10/17/2023
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Avelumab plus cetuximab...
10/17/2023
Oncology
News
FDA Approves Adjuvant Nivolumab for Resected, Stage IIB/C Melanoma
10/16/2023
Based on findings from the phase 3 CHECKMATE-76K trial, the FDA has approved nivolumab in the adjuvant setting for patients 12 and older with completely resected stage IIB/C melanoma.
Based on findings from the phase 3 CHECKMATE-76K trial, the FDA has approved nivolumab in the adjuvant setting for patients 12 and older with completely resected stage IIB/C melanoma.
Based on findings from the phase...
10/16/2023
Oncology
News
Addition of Binimetinib to Encorafenib Demonstrated Efficacy, Safety Among Patients With Advanced, Unresectable BRAFV600-Mutant Melanoma
09/11/2023
According to results from part 2 of the phase 3 COLUMBUS trial, the addition of binimetinib to encorafenib improved progression-free survival, overall response rate, and had a favorable safety profile compared with encorafenib alone among...
According to results from part 2 of the phase 3 COLUMBUS trial, the addition of binimetinib to encorafenib improved progression-free survival, overall response rate, and had a favorable safety profile compared with encorafenib alone among...
According to results from part 2...
09/11/2023
Oncology
News
Perioperative Pembrolizumab Demonstrates Long-Term Safety, Efficacy Among Patients With Late-Stage, Resectable Cutaneous Melanoma
09/01/2023
According to 5-year follow-up results from a phase 1b study, pembrolizumab is safe and effective in both the neoadjuvant and adjuvant settings among patients with resectable, stage III to IV cutaneous melanoma who have achieved a pathological...
According to 5-year follow-up results from a phase 1b study, pembrolizumab is safe and effective in both the neoadjuvant and adjuvant settings among patients with resectable, stage III to IV cutaneous melanoma who have achieved a pathological...
According to 5-year follow-up...
09/01/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement